Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy - PubMed (original) (raw)
Review
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy
M Selman et al. Ann Intern Med. 2001.
Abstract
Idiopathic pulmonary fibrosis is a progressive and usually fatal lung disease characterized by fibroblast proliferation and extracellular matrix remodeling, which result in irreversible distortion of the lung's architecture. Although the pathogenetic mechanisms remain to be determined, the prevailing hypothesis holds that fibrosis is preceded and provoked by a chronic inflammatory process that injures the lung and modulates lung fibrogenesis, leading to the end-stage fibrotic scar. However, there is little evidence that inflammation is prominent in early disease, and it is unclear whether inflammation is relevant to the development of the fibrotic process. Evidence suggests that inflammation does not play a pivotal role. Inflammation is not a prominent histopathologic finding, and epithelial injury in the absence of ongoing inflammation is sufficient to stimulate the development of fibrosis. In addition, the inflammatory response to a lung fibrogenic insult is not necessarily related to the fibrotic response. Clinical measurements of inflammation fail to correlate with stage or outcome, and potent anti-inflammatory therapy does not improve outcome. This review presents a growing body of evidence suggesting that idiopathic pulmonary fibrosis involves abnormal wound healing in response to multiple, microscopic sites of ongoing alveolar epithelial injury and activation associated with the formation of patchy fibroblast-myofibroblast foci, which evolve to fibrosis. Progress in understanding the fibrogenic mechanisms in the lung is likely to yield more effective therapies.
Similar articles
- Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.
White ES, Lazar MH, Thannickal VJ. White ES, et al. J Pathol. 2003 Nov;201(3):343-54. doi: 10.1002/path.1446. J Pathol. 2003. PMID: 14595745 Free PMC article. Review. - Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.
Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd. Selman M, et al. Drugs. 2004;64(4):405-30. doi: 10.2165/00003495-200464040-00005. Drugs. 2004. PMID: 14969575 Review. - Idiopathic pulmonary fibrosis: new insights in its pathogenesis.
Pardo A, Selman M. Pardo A, et al. Int J Biochem Cell Biol. 2002 Dec;34(12):1534-8. doi: 10.1016/s1357-2725(02)00091-2. Int J Biochem Cell Biol. 2002. PMID: 12379275 Review. - Molecular mechanisms of pulmonary fibrosis.
Pardo A, Selman M. Pardo A, et al. Front Biosci. 2002 Aug 1;7:d1743-61. doi: 10.2741/pardo. Front Biosci. 2002. PMID: 12133818 Review. - New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy.
Gharaee-Kermani M, Gyetko MR, Hu B, Phan SH. Gharaee-Kermani M, et al. Pharm Res. 2007 May;24(5):819-41. doi: 10.1007/s11095-006-9216-x. Epub 2007 Mar 1. Pharm Res. 2007. PMID: 17333393 Review.
Cited by
- The inter-connection between fibrosis and microvascular remodeling in idiopathic pulmonary fibrosis: Reality or just a phenomenon.
Mlika M, Bacha S, Braham E, El Mezni F. Mlika M, et al. Respir Med Case Rep. 2015 Dec 17;17:30-3. doi: 10.1016/j.rmcr.2015.11.006. eCollection 2016. Respir Med Case Rep. 2015. PMID: 27222781 Free PMC article. - Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis.
McGrath EE, Lawrie A, Marriott HM, Mercer P, Cross SS, Arnold N, Singleton V, Thompson AA, Walmsley SR, Renshaw SA, Sabroe I, Chambers RC, Dockrell DH, Whyte MK. McGrath EE, et al. Thorax. 2012 Sep;67(9):796-803. doi: 10.1136/thoraxjnl-2011-200863. Epub 2012 Apr 11. Thorax. 2012. PMID: 22496351 Free PMC article. - Overexpression of inhibitor of DNA-binding 2 attenuates pulmonary fibrosis through regulation of c-Abl and Twist.
Yang J, Velikoff M, Agarwal M, Disayabutr S, Wolters PJ, Kim KK. Yang J, et al. Am J Pathol. 2015 Apr;185(4):1001-11. doi: 10.1016/j.ajpath.2014.12.008. Epub 2015 Feb 3. Am J Pathol. 2015. PMID: 25661109 Free PMC article. - Pro-Fibrotic Effects of CCL18 on Human Lung Fibroblasts Are Mediated via CCR6.
Höhne K, Wagenknecht A, Maier C, Engelhard P, Goldmann T, Schließmann SJ, Plönes T, Trepel M, Eibel H, Müller-Quernheim J, Zissel G. Höhne K, et al. Cells. 2024 Jan 26;13(3):238. doi: 10.3390/cells13030238. Cells. 2024. PMID: 38334630 Free PMC article. - Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis.
Balestro E, Calabrese F, Turato G, Lunardi F, Bazzan E, Marulli G, Biondini D, Rossi E, Sanduzzi A, Rea F, Rigobello C, Gregori D, Baraldo S, Spagnolo P, Cosio MG, Saetta M. Balestro E, et al. PLoS One. 2016 May 9;11(5):e0154516. doi: 10.1371/journal.pone.0154516. eCollection 2016. PLoS One. 2016. PMID: 27159038 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical